Fig. 1From: Levels of extracellular matrix metabolites are associated with changes in Ankylosing Spondylitis Disease Activity Score and MRI inflammation scores in patients with axial spondyloarthritis during TNF inhibitor therapyTime course of biomarkers in response to TNF-α inhibitor therapy. A Type I collagen formation, PRO-C1; B type III collagen formation, PRO-C3; C type IV collagen turnover, PRO-C4; D type VI collagen formation, PRO-C6; E type III collagen degradation, C3M; F type IV collagen degradation, C4M; G type VI collagen degradation, C6M; H type VII collagen degradation, C7M; I type X collagen degradation, C10C; J C-reactive metabolite, CRPM; K elastin degradation, EL-NE; L citrullination and degradation of vimentin, VICM; and M C-reactive protein, CRP. Time course is shown as median ± 95% CI. *p<0.05 **p<0.01, ***p<0.001, ****p<0.0001Back to article page